Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
2009 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Towards the convergent therapeutic potential of G protein-coupled receptors in autism spectrum disorders.
Annamneedi A, Gora C, Dudas A, Leray X, Bozon V, Crépieux P, Pellissier LP. Annamneedi A, et al. Among authors: bozon v. Br J Pharmacol. 2023 Aug 13. doi: 10.1111/bph.16216. Online ahead of print. Br J Pharmacol. 2023. PMID: 37574491 Review.
Despite hundreds of GPCRs being expressed in the brain, only 23 are genetically associated with ASD according to the Simons Foundation Autism Research Initiative (SFARI) gene database: oxytocin OTR; vasopressin V(1A) and V(1B) ; metabotropic glutamate mGlu(5) and mG …
Despite hundreds of GPCRs being expressed in the brain, only 23 are genetically associated with ASD according to the Simons Foundation Autis …
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Camacho LH, et al. Among authors: bozon va. J Clin Oncol. 2009 Mar 1;27(7):1075-81. doi: 10.1200/JCO.2008.19.2435. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139427 Clinical Trial.
Serious AEs were also less frequent in the 15 mg/kg once every 3 months cohort (9% v 23% in 10 mg/kg arm). CONCLUSION: Multiple infusions of tremelimumab were generally tolerable and demonstrated single-agent antitumor activity. ...
Serious AEs were also less frequent in the 15 mg/kg once every 3 months cohort (9% v 23% in 10 mg/kg arm). CONCLUSION: Multiple infus …
IDS gene-pseudogene exchange responsible for an intragenic deletion in a Hunter patient.
Birot AM, Bouton O, Froissart R, Maire I, Bozon D. Birot AM, et al. Among authors: bozon d. Hum Mutat. 1996;8(1):44-50. doi: 10.1002/(SICI)1098-1004(1996)8:1<44::AID-HUMU6>3.0.CO;2-P. Hum Mutat. 1996. PMID: 8807335
Patient 1 has a partial deletion that removes exons I to VI and extends about 200 kb upstream of the IDS gene. Patient 2 has an internal deletion of exons IV, V, VI, and VII, which results from an IDS gene-pseudogene exchange between highly homologous regions. ...
Patient 1 has a partial deletion that removes exons I to VI and extends about 200 kb upstream of the IDS gene. Patient 2 has an internal del …
Capillary electrophoretic analysis of DNA restriction fragments and PCR products for polymorphism and mutation studies in cystic fibrosis and Gaucher's disease.
Bory C, Chantin C, Bozon D. Bory C, et al. Among authors: bozon d. J Pharm Biomed Anal. 1995 Apr;13(4-5):511-4. doi: 10.1016/0731-7085(95)01314-b. J Pharm Biomed Anal. 1995. PMID: 9696564
Electrokinetic injection was used (5-7 kV for 5-20 s), the applied field being 300 V cm-1 for an effective length of 7, 20 or 30 cm and 100 microns i.d., with Tris-borate buffer containing urea. ...
Electrokinetic injection was used (5-7 kV for 5-20 s), the applied field being 300 V cm-1 for an effective length of 7, 20 or 30 cm a …